Tg Drug Patent Portfolio
Tg owns 1 orange book drug protected by 8 US patents Given below is the list of Tg's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10414773 | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations | 26 May, 2035 | Active |
| US10947244 | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations | 26 May, 2035 | Active |
| US9969740 | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations | 26 May, 2035 | Active |
| US10072013 | Selective PI3K delta inhibitors | 02 Jul, 2033 | Active |
| US10570142 | Selective PI3K delta inhibitors | 02 Jul, 2033 | Active |
| US10981919 | Selective PI3K delta inhibitors | 02 Jul, 2033 | Active |
| US9150579 | Selective PI3K delta inhibitors | 02 Jul, 2033 | Active |
| US9669033 | Selective PI3K delta inhibitors | 02 Jul, 2033 | Active |
Latest Legal Activities on Tg's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Tg.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent | 14 Jul, 2025 | US9669033 |
| Expire Patent | 26 May, 2025 | US10981919 |
| FDA Final Eligibility Letter | 20 May, 2025 | US9150579 |
| Information Disclosure Statement (IDS) Filed | 20 May, 2025 | US10570142 |
| FDA Final Eligibility Letter | 20 May, 2025 | US10570142 |
| Information Disclosure Statement (IDS) Filed | 20 May, 2025 | US9669033 |
| FDA Final Eligibility Letter | 20 May, 2025 | US9669033 |
| FDA Final Eligibility Letter | 20 May, 2025 | US10072013 |
| Information Disclosure Statement (IDS) Filed | 20 May, 2025 | US9150579 |
| Information Disclosure Statement (IDS) Filed | 20 May, 2025 | US10072013 |
| Expire Patent | 21 Apr, 2025 | US10947244 |
| Maintenance Fee Reminder Mailed | 27 Jan, 2025 | US9669033 |
| Maintenance Fee Reminder Mailed | 09 Dec, 2024 | US10981919 |
| Maintenance Fee Reminder Mailed | 04 Nov, 2024 | US10947244 |
| transaction for FDA Determination of Regulatory Review Period | 30 Jan, 2024 | US10072013 |
Tg's Family Patents
Tg drugs have patent protection in a total of 33 countries. It's US patent count contributes only to 15.4% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Tg Drug List
Given below is the complete list of Tg's drugs and the patents protecting them.
1. Ukoniq
Ukoniq is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10414773 | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
26 May, 2035
(9 years from now)
| Active |
| US10947244 | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
26 May, 2035
(9 years from now)
| Active |
| US9969740 | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
26 May, 2035
(9 years from now)
| Active |
| US10072013 | Selective PI3K delta inhibitors |
02 Jul, 2033
(7 years from now)
| Active |
| US10570142 | Selective PI3K delta inhibitors |
02 Jul, 2033
(7 years from now)
| Active |
| US10981919 | Selective PI3K delta inhibitors |
02 Jul, 2033
(7 years from now)
| Active |
| US9150579 | Selective PI3K delta inhibitors |
02 Jul, 2033
(7 years from now)
| Active |
| US9669033 | Selective PI3K delta inhibitors |
02 Jul, 2033
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ukoniq's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List